新辅助化疗对乳腺癌外周血微转移因子的影响  

Neoadjuvant Chemotherapy for Peripheral Blood Micrometastasis Factors in Patients of Breast Cancer

作　　者：和钢[1] 乐东海[1] 杨峂[1] 张顺[1] 李克强[1] 

机构地区：[1]浙江省宁波市第二医院,宁波315000

出　　处：《浙江中西医结合杂志》2009年第8期479-481,共3页Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:观察新辅助化疗对乳腺癌外周血微转移因子的影响。方法:以48例具备新辅助化疗条件的乳腺癌患者为研究对象,采用RT-PCR技术,联合检测外周血中CK-19 mRNA、VEGF mRNA和hMAM mRNA的表达,观察新辅助化疗前后血微转移因子变化。结果:本组乳腺癌微转移因子阳性率在病理分级中差异无显著性意义(P>0.05);在分期中,分期越高阳性率越高(P<0.05);化疗方案可影响微转移因子阳性率的变化(P<0.01)。结论:通过检测乳腺癌患者外周血中微转移因子,有可能成为判断乳腺癌预后和指导治疗的指标。Objective： To explore the influence of neoadjuvant chemotherapy on peripheral micrometastasis factors in breast cancer. Methods： CK-19mRNA, VEGFmRNA and hMAMmRNA in peripheral blood of 48 breast cancer patients were detected using RT-PCR before and after neoadjuvant chemotherapy. Results： No significant difference in the breast micrometastasis factors was noted in different pathological stages （ P 〉 0.05 ） ; the positive rate of micrometastasis factors was higher in upper clinical stages（ P 〈 0. 05 ）. Chemotherapy had positive effect on micrometastasis factors （ P 〈 0. 01 ）.Conclusion ：The factors of peripheral micrometastasis could be tested for breast cancer patients, guiding prognosis and treatment.

关 键 词：乳腺癌 新辅助化疗 微转移因子 逆转录聚合酶链反应 

分 类 号：R737.9[医药卫生—肿瘤] R392-33[医药卫生—临床医学]